IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Business Wire
BETHESDA, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (NYSE: IGC) announced today that the Institutional Review Board (“IRB”), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease.“With this important approval, our Company can implement a 50-person double-blind placebo-controlled trial that we hope begins to prove the efficacy of micro-doses of cannabis in combination with other natural compounds on the behavior of patients suffering from Alzheimer’s. We expect to measure improvements in neuropsychiatric symptoms (“NPI”) such as delusions, agitation/aggression, dysphoria, anxiety, sleep disorder, disinhibition, irritability, apathy and eating abnormalities, among others,” stated Ram Mukunda, CEO.In 2017, IGC acquired a patent filing from the University of South Florida (USF) that showed
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoBusiness Wire
- IGC Pharma Adds Advisor in Artificial IntelligenceBusiness Wire
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockBusiness Wire
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationBusiness Wire
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024Business Wire
IGC
Sec Filings
- 5/3/24 - Form EFFECT
- 4/18/24 - Form S-3
- 4/5/24 - Form 8-K
- IGC's page on the SEC website